TREM-2与肿瘤

国际肿瘤学杂志››2021,Vol. 48››Issue (2): 101-104.doi:10.3760/cma.j.cn371439-20200611-00019

李利婷¹, 高晓玲²()

¹山西医科大学第二临床医学院,太原 030001
²山西医科大学第二医院呼吸与危重症医学科,太原 030001

收稿日期:2020-06-11修回日期:2020-07-02出版日期:2021-02-08发布日期:2021-03-11
通讯作者:高晓玲 E-mail:yihexiyuan@qq.com
基金资助:
国家自然科学基金(81870076)

TREM-2 and tumors

Li Liting¹, Gao Xiaoling²()

¹Second School of Clinical Medicine, Shanxi Medical University, Taiyuan 030001, China
²Department of Respiratory and Critical Care Medicine, Second Hospital of Shanxi Medical University, Taiyuan 030001, China

Received:2020-06-11Revised:2020-07-02Online:2021-02-08Published:2021-03-11
Contact:Gao Xiaoling E-mail:yihexiyuan@qq.com
Supported by:
National Natural Science Foundation of China(81870076)

摘要/Abstract

摘要：

髓样细胞触发受体-2(TREM-2)是新近发现的免疫球蛋白受体,在炎症和免疫反应中扮演重要角色。近年来有研究表明,TREM-2在多种恶性肿瘤如肺癌、胃癌、肝癌、结直肠癌、肾癌、神经胶质瘤中异常表达,其可通过不同信号通路广泛参与恶性肿瘤的发生、发展、侵袭和转移过程。TREM-2可为恶性肿瘤的诊治及改善预后提供参考。

关键词:肿瘤,预后,髓样细胞触发受体-2

Abstract:

Triggering receptors expressed on myeloid cells-2 (TREM-2) is a newly discovered immunoglobulin receptor, which plays an important role in inflammation and immunoreaction. Several recent studies have shown that TREM-2 is aberrantly expressed in various types of cancers such as lung cancer, gastric cancer, liver cancer, colorectal cancer, renal carcinoma and glioma, and it is widely participated in regulating malignant tumor initiation, progression, invasion and metastasis through different signal pathways. TREM-2 is expected to provide evidence for the diagnosis and treatment of malignant tumors.

Key words:Neoplasms,Prognosis,Triggering receptors expressed on myeloid cells-2

李利婷, 高晓玲. TREM-2与肿瘤[J]. 国际肿瘤学杂志, 2021, 48(2): 101-104.

Li Liting, Gao Xiaoling. TREM-2 and tumors[J]. Journal of International Oncology, 2021, 48(2): 101-104.

参考文献29

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi:10.3322/caac.21492pmid:30207593
[2]	Poliani PL, Wang Y, Fontana E, et al. TREM2 sustains microglial expansion during aging and response to demyelination[J]. J Clin Invest, 2015,125(5):2161-2170. DOI: 10.1172/JCI77983. pmid:25893602
[3]	Zhong L, Chen XF, Zhang ZL, et al. DAP12 stabilizes the C-terminal fragment of the triggering receptor expressed on myeloid cells-2 (TREM2) and protects against LPS-induced pro-inflammatory response[J]. J Biol Chem, 2015,290(25):15866-15877. DOI: 10.1074/jbc.M115.645986. doi:10.1074/jbc.M115.645986pmid:25957402
[4]	Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight[J]. Nat Rev Immunol, 2018,18(12):759-772. DOI: 10.1038/s41577-018-0051-1. doi:10.1038/s41577-018-0051-1pmid:30140051
[5]	Katsel P, Haroutunian V. Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old[J]. Dialogues Clin Neurosci, 2019,21(1):7-19. DOI: 10.31887/DCNS.2019.21.1/vharoutunian. pmid:31607776
[6]	Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis[J]. Nat Rev Neurosci, 2016,17(4):201-207. DOI: 10.1038/nrn.2016.7. doi:10.1038/nrn.2016.7pmid:26911435
[7]	孙可欣, 郑荣寿, 张思维. 2015年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2019,28(1):1-11. DOI: 10.11735/j.issn.1004-0242.2019.01.A001.
[8]	潘志杰. 负向免疫调控分子TREM-2在肺癌发病中作用及机制的研究[D]. 杭州: 浙江大学, 2013.
[9]	Yao Y, Li H, Chen J, et al. TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer[J]. Oncotarget, 2016,7(20):29620-29634. DOI: 10.18632/oncotarget.8813. doi:10.18632/oncotarget.8813pmid:27102437
[10]	Thomson AW, Metes DW, Ezzelarab MB, et al. Regulatory dendri-tic cells for human organ transplantation[J]. Transplant Rev (Orlando), 2019,33(3):130-136. DOI: 10.1016/j.trre.2019.05.001. doi:10.1016/j.trre.2019.05.001
[11]	Hamerman JA, Jarjoura JR, Humphrey MB, et al. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12[J]. J Immunol, 2006,177(4):2051-2055. DOI: 10.4049/jimmunol.177.4.2051. doi:10.4049/jimmunol.177.4.2051pmid:16887962
[12]	Zhu M, Wang Q, Luo Z, et al. Development and validation of a prognostic signature for preoperative prediction of overall survival in gastric cancer patients[J]. Onco Targets Ther, 2018,11:8711-8722. DOI: 10.2147/OTT.S181741. doi:10.2147/OTT.S181741pmid:30584329
[13]	Zhang X, Wang W, Li P, et al. High TREM2 expression correlates with poor prognosis in gastric cancer[J]. Hum Pathol, 2018,72:91-99. DOI: 10.1016/j.humpath.2017.10.026. doi:10.1016/j.humpath.2017.10.026pmid:29104108
[14]	冯春念, 马婷婷, 赵千秋, 等. 胃癌组织TREM2表达变化及其临床意义[J]. 山东医药, 2018,58(44):78-80. DOI: 10.3969/j.issn.1002-266X.2018.44.023.
[15]	Zhang SL, Chen TS, Xiao L, et al. TREM2 siRNA inhibits cell proliferation of human liver cancer cell lines[J]. Int J Clin Exp Pathol, 2016,9(4):4318-4328.
[16]	Tang W, Lv B, Yang B, et al. TREM2 acts as a tumor suppressor in hepatocellular carcinoma by targeting the PI3K/Akt/β-catenin pathway[J]. Oncogenesis, 2019,8(2):9. DOI: 10.1038/s41389-018-0115-x. doi:10.1038/s41389-018-0115-xpmid:30683932
[17]	Wands JR, Kim M. WNT/β-catenin signaling and hepatocellular carcinoma[J]. Hepatology, 2014,60(2):452-454. DOI: 10.1002/hep.27081. doi:10.1002/hep.27081pmid:24644061
[18]	Peng Q, Malhotra S, Torchia JA, et al. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1[J]. Sci Signal, 2010,3(122):ra38. DOI: 10.1126/scisignal.2000500. doi:10.1126/scisignal.2000500pmid:20484116
[19]	Genua M, Monico MC, D'Alessio S, et al. Intestinal microbiota defined by the absence of the triggering receptor expressed on myeloid cells type-2 (TREM-2) is transmissible and protects from colitis associated cancer[J]. Gastroenterology, 2014,146(5 suppl 1):S42. DOI: 10.1016/S0016-5085(14)60144-X.
[20]	Kim SM, Kim EM, Ji KY, et al. TREM2 acts as a tumor suppressor in colorectal carcinoma through Wnt1/β-catenin and Erk signaling[J]. Cancers (Basel), 2019,11(9):1315. DOI: 10.3390/can-cers11091315. doi:10.3390/cancers11091315
[21]	Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017,3:17009. DOI: 10.1038/nrdp.2017.9. doi:10.1038/nrdp.2017.9pmid:28276433
[22]	Zhang H, Sheng L, Tao J, et al. Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway[J]. Int J Oncol, 2016,49(6):2498-2506. DOI: 10.3892/ijo.2016.3740. doi:10.3892/ijo.2016.3740pmid:27779645
[23]	周伟敏. PDK1通过PI3K/AKT信号通路介导肾细胞癌生物学行为及机制研究[D]. 南昌: 南昌大学, 2019.
[24]	Sun M, Zhu M, Chen k, et al. TREM-2 promotes host resistance against pseudomonas aeruginosa infection by suppressing corneal inflammation via a PI3K/Akt signaling pathway[J]. Invest Ophthalmol Vis Sci, 2013,54(5):3451-3462. DOI: 10.1167/iovs.12-10938. doi:10.1167/iovs.12-10938pmid:23611998
[25]	Zhu M, Li D, Wu Y, et al. TREM-2 promotes macrophage-mediated eradication of pseudomonas aeruginosa via a PI3K/Akt pathway[J]. Scand J Immunol, 2014,79(3):187-196. DOI: 10.1111/sji.12148. doi:10.1111/sji.12148
[26]	Malaney P, Uversky VN, Davé V. PTEN proteoforms in biology and disease[J]. Cell Mol Life Sci, 2017,74(15):2783-2794. DOI: 10.1007/s00018-017-2500-6. doi:10.1007/s00018-017-2500-6pmid:28289760
[27]	Fruman DA, Chiu H, Hopkins BD, et al. The PI3K pathway in human disease[J]. Cell, 2017,170(4):605-635. DOI: 10.1016/j.cell.2017.07.029. doi:10.1016/j.cell.2017.07.029pmid:28802037
[28]	Wang XQ, Tao BB, Li B, et al. Overexpression of TREM2 enhances glioma cell proliferation and invasion: a therapeutic target in human glioma[J]. Oncotarget, 2016,7(3):2354-2366. DOI: 10.18632/oncotarget.6221. doi:10.18632/oncotarget.6221pmid:26506595
[29]	Maru SV, Holloway KA, Flynn G, et al. Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation[J]. J Neuroimmunol, 2008,199(1-2):35-45. DOI: 10.1016/j.jneuroim.2008.04.029. doi:10.1016/j.jneuroim.2008.04.029pmid:18538864

TREM-2与肿瘤

TREM-2 and tumors

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献29

相关文章15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[14]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[15]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.